Armata Pharmaceuticals | 10-Q: FY2025 Q2 EPS: USD -0.45

EPS: As of FY2025 Q2, the actual value is USD -0.45.

Operating Loss

• Operating loss for the three months ended June 30, 2025, was $6.8 million, compared to $11.9 million for the same period in 2024, representing a decrease of 42.6%.

Net Loss

• Net loss for the three months ended June 30, 2025, was $16.3 million, compared to a net income of $9.0 million for the same period in 2024.

Research and Development Expenses

• Research and development expenses decreased by $2.1 million, from $8.5 million for the three months ended June 30, 2024, to $6.4 million for the same period in 2025, primarily due to decreased clinical trial costs.

General and Administrative Expenses

• General and administrative expenses were $2.6 million for the three months ended June 30, 2025, a decrease from $3.4 million for the same period in 2024.

Cash Flow

• Net cash used in operating activities was $14.8 million for the six months ended June 30, 2025, compared to $20.8 million for the same period in 2024.

Future Outlook and Strategy

Core Business Focus

• Armata Pharmaceuticals, Inc. plans to continue the development of its phage-based therapeutics, focusing on advancing its lead candidates, AP-PA02 and AP-SA02, through clinical trials. The company aims to secure additional funding to support these initiatives and potentially resume clinical development of AP-PA02 for non-cystic fibrosis bronchiectasis.

Non-Core Business

• The company is exploring potential strategic partnerships to further advance its programs and is considering revising its clinical trial protocols to include additional indications for its phage products.